BiotechTube

Tocilizumab + NSAIDs + CSs + MTX

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Juvenile Idiopathic Arthritis

Conditions

Juvenile Idiopathic Arthritis

Trial Timeline

Apr 26, 2018 → Aug 5, 2022

NCT ID
NCT03301883

About Tocilizumab + NSAIDs + CSs + MTX

Tocilizumab + NSAIDs + CSs + MTX is a approved stage product being developed by Roche for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03301883. Target conditions include Juvenile Idiopathic Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis were approved

Approved (0) Terminated (2) Active (18)
🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄AdalimumabEisaiPhase 3
🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03301883ApprovedCompleted

Competing Products

20 competing products in Juvenile Idiopathic Arthritis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
37
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
AdalimumabEisaiPhase 3
40
AbataceptOno PharmaceuticalPhase 3
40
Ixekizumab + AdalimumabEli LillyPhase 3
44
Baricitinib + PlaceboEli LillyPhase 3
40
BaricitinibEli LillyPhase 3
47
Baricitinib + TocilizumabEli LillyPhase 3
47
adalimumab + MethotrexateAbbViePre-clinical
26
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
47
Adalimumab + RisankizumabAbbViePhase 3
47
AdalimumabAbbViePhase 3
40
naproxen + esomeprazoleAstraZenecaPhase 1
29
Alendronate (Fosamax)MerckPre-clinical
26
canakinumabNovartisPhase 3
40
SecukinumabNovartisPhase 1
36